<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118535</article-id><article-id pub-id-type="publisher-id">ACM-44758</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_41527305.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  射血分数降低的急性心力衰竭患者的临床特点及危险因素分析
  Analysis of Clinical Characteristics and Risk Factors for Acute Heart Failure Patients with Reduced Ejection Fraction
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>吴</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>利宏</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学院，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>浙江省人民医院，浙江 杭州 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3652</fpage><lpage>3658</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分析左心室射血分数(LVEF)降低的急性心力衰竭(AHF)患者的临床特点及危险因素。方法：选取浙江省人民医院2019年1月至2020年1月首次入院的AHF患者162例，根据LVEF将患者分为2组，其中LVEF ≤ 40%为射血分数降低组，共94例，LVEF ≥ 50%为射血分数保留组，共68例。记录上述患者基础资料及实验室指标，并随访1年，记录随访期内再住院及死亡人数。比较两组患者的临床资料，采用多因素logistic回归分析射血分数降低的AHF患者的临床特点及再住院的危险因素。结果：射血分数降低组AHF患者收缩压、尿酸、高密度脂蛋白胆固醇均明显低于射血分数保留组的AHF患者(均P &lt; 0.05)，舒张压、心率、糖化血红蛋白A1、白蛋白、脑利钠肽、脑钠素N端前体肽、肌钙蛋白I水平均明显高于射血分数保留组的AHF患者(均P &lt; 0.05)；射血分数降低组AHF患者再住院率及1年内死亡率高于射血分数保留组(均P &lt; 0.05)。多因素logistic回归分析发现性别、年龄、心率、白蛋白、糖化血红蛋白A1、脑利钠肽是影响射血分数降低的AHF患者再住院的独立危险因素(均P &lt; 0.05)。结论：左心室射血分数减少的AHF患者的1年内预后较射血分数保留的AHF患者差，临床上应加强对该类患者的随访，改善血压、心率的控制水平，定期监测白蛋白、糖化血红蛋白A1、脑利钠肽、脑钠素N端前体肽水平，降低再住院及死亡率。
   Objective: Analysis of clinical characteristics and risk factors for acute heart failure (AHF) patients with reduced ejection fraction. Methods: The AHF patients admitted to Zhejiang Provincial People’s Hospital from January 2019 to January 2020 were selected and divided into a reduced ejection fraction group of 94 cases and a reserved ejection fraction group of 68 cases according to the number of admissions. The above patient basic information and laboratory indicators were recorded, followed up for 1 year, recorded in the recycling period and the number of deaths during the period. The clinical data of the two groups of patients were compared and used multivariate logistic regression to analyze influencing factors of rehospitalization of AHF patients with reduced ejection fraction. Results: The systolic blood pressure, uric acid and high density lipoprotein cholesterol of the reduced ejection fraction group were significantly lower than those of the reserved ejection fraction group (all P &lt; 0.05). Diastolic blood pressure, heart rate, glycated hemoglobin A1, albumin, brain sodium peptide, sodium sodium N-end peptide, troponin I of the reduced ejection fraction group were significantly higher than those of the reserved ejection fraction group (all P &lt; 0.05). The rehospitalization rate and the one-year mortality in the 1 year of the mortality of AHF patients in reduced ejection fraction group were higher than that of reserved ejection fraction group (P &lt; 0.05). Multivariate logistic regression analysis shows that gender, age, heart rate, albumin, glycalated hemoglobin A1, brain sodium peptide are independent risk factors that affect the rehospitalization of AHF patients in reduced ejection fraction group. Conclusion: Acute heart failure patients with reduced ejection fraction have poor prognosis within 1 year than patients with reserved ejection fraction. The clinical should strengthen the follow-up of this class and improve blood pressure, heart rate control level, regular monitoring albumin, glycated hemoglobin A1, brain sodium peptide, sodium sodium N-ternary peptide level, reducing re-hospitalization and mortality.
 
</p></abstract><kwd-group><kwd>急性心力衰竭，左心室射血分数，临床特点，危险因素, Acute Heart Failure</kwd><kwd> Left Ventricular Ejection Fraction</kwd><kwd> Clinical Characteristics</kwd><kwd> Risk Factors</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分析左心室射血分数(LVEF)降低的急性心力衰竭(AHF)患者的临床特点及危险因素。方法：选取浙江省人民医院2019年1月至2020年1月首次入院的AHF患者162例，根据LVEF将患者分为2组，其中LVEF ≤ 40%为射血分数降低组，共94例，LVEF ≥ 50%为射血分数保留组，共68例。记录上述患者基础资料及实验室指标，并随访1年，记录随访期内再住院及死亡人数。比较两组患者的临床资料，采用多因素logistic回归分析射血分数降低的AHF患者的临床特点及再住院的危险因素。结果：射血分数降低组AHF患者收缩压、尿酸、高密度脂蛋白胆固醇均明显低于射血分数保留组的AHF患者(均P &lt; 0.05)，舒张压、心率、糖化血红蛋白A1、白蛋白、脑利钠肽、脑钠素N端前体肽、肌钙蛋白I水平均明显高于射血分数保留组的AHF患者(均P &lt; 0.05)；射血分数降低组AHF患者再住院率及1年内死亡率高于射血分数保留组(均P &lt; 0.05)。多因素logistic回归分析发现性别、年龄、心率、白蛋白、糖化血红蛋白A1、脑利钠肽是影响射血分数降低的AHF患者再住院的独立危险因素(均P &lt; 0.05)。结论：左心室射血分数减少的AHF患者的1年内预后较射血分数保留的AHF患者差，临床上应加强对该类患者的随访，改善血压、心率的控制水平，定期监测白蛋白、糖化血红蛋白A1、脑利钠肽、脑钠素N端前体肽水平，降低再住院及死亡率。</p></sec><sec id="s2"><title>关键词</title><p>急性心力衰竭，左心室射血分数，临床特点，危险因素</p></sec><sec id="s3"><title>Analysis of Clinical Characteristics and Risk Factors for Acute Heart Failure Patients with Reduced Ejection Fraction<sup> </sup></title><p>Fei Wu<sup>1</sup>, Lihong Wang<sup>2</sup></p><p><sup>1</sup>Medical College, Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Zhejiang People’s Hospital, Hangzhou Zhejiang</p><p><img src="//html.hanspub.org/file/52-1572525x4_hanspub.png?20210826083353156" /></p><p>Received: Jul. 23<sup>rd</sup>, 2021; accepted: Aug. 18<sup>th</sup>, 2021; published: Aug. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/52-1572525x5_hanspub.png?20210826083353156" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: Analysis of clinical characteristics and risk factors for acute heart failure (AHF) patients with reduced ejection fraction. Methods: The AHF patients admitted to Zhejiang Provincial People’s Hospital from January 2019 to January 2020 were selected and divided into a reduced ejection fraction group of 94 cases and a reserved ejection fraction group of 68 cases according to the number of admissions. The above patient basic information and laboratory indicators were recorded, followed up for 1 year, recorded in the recycling period and the number of deaths during the period. The clinical data of the two groups of patients were compared and used multivariate logistic regression to analyze influencing factors of rehospitalization of AHF patients with reduced ejection fraction. Results: The systolic blood pressure, uric acid and high density lipoprotein cholesterol of the reduced ejection fraction group were significantly lower than those of the reserved ejection fraction group (all P &lt; 0.05). Diastolic blood pressure, heart rate, glycated hemoglobin A1, albumin, brain sodium peptide, sodium sodium N-end peptide, troponin I of the reduced ejection fraction group were significantly higher than those of the reserved ejection fraction group (all P &lt; 0.05). The rehospitalization rate and the one-year mortality in the 1 year of the mortality of AHF patients in reduced ejection fraction group were higher than that of reserved ejection fraction group (P &lt; 0.05). Multivariate logistic regression analysis shows that gender, age, heart rate, albumin, glycalated hemoglobin A1, brain sodium peptide are independent risk factors that affect the rehospitalization of AHF patients in reduced ejection fraction group. Conclusion: Acute heart failure patients with reduced ejection fraction have poor prognosis within 1 year than patients with reserved ejection fraction. The clinical should strengthen the follow-up of this class and improve blood pressure, heart rate control level, regular monitoring albumin, glycated hemoglobin A1, brain sodium peptide, sodium sodium N-ternary peptide level, reducing re-hospitalization and mortality.</p><p>Keywords:Acute Heart Failure, Left Ventricular Ejection Fraction, Clinical Characteristics, Risk Factors</p><disp-formula id="hanspub.44758-formula28"><graphic xlink:href="//html.hanspub.org/file/52-1572525x6_hanspub.png?20210826083353156"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/52-1572525x7_hanspub.png?20210826083353156" /> <img src="//html.hanspub.org/file/52-1572525x8_hanspub.png?20210826083353156" /></p></sec><sec id="s5"><title>1. 引言</title><p>心力衰竭(heart failure, HF)是一组以肺循环、体循环淤血，机体组织器官血液灌注不足为主要临床表现的综合征，当上述症状和体征突然发生恶化时，就会引起急性心力衰竭(acute heart failure, AHF) [<xref ref-type="bibr" rid="hanspub.44758-ref1">1</xref>]。左室射血分数(left veutdcular ejection fraction, LVEF)是评估心力衰竭的重要指标，按照LVEF将AHF分为射血分数降低(LVEF ≤ 40%)的急性心力衰竭患者和射血分数保留(LVEF ≥ 50%)的急性心力衰竭患者 [<xref ref-type="bibr" rid="hanspub.44758-ref2">2</xref>]。回顾性研究显示，心力衰竭在人群中具有较高的发病率和死亡率，虽然近年来死亡率呈下降趋势 [<xref ref-type="bibr" rid="hanspub.44758-ref3">3</xref>]，但射血分数降低的AHF病人预后仍较差，再住院的危险因素尚未明确。本文就影响LVEF降低的AHF患者住院危险因素作一分析，现将结果作如下报道。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 对象</title><p>选取2019年1月至2020年1月浙江省人民医院心血管内科收治的162例AHF患者为研究对象，其中男98例，女64例；年龄73.7 &#177; 13.2岁。所有患者AHF诊断均符合2018年中华医学会心血管病学分会急性心力衰竭诊断和治疗指南 [<xref ref-type="bibr" rid="hanspub.44758-ref4">4</xref>]。排除标准：1) 治疗依从性差，不能配合研究者；2) 3个月内发生过急性心肌梗死的患者；3) 合并严重的肝肾疾病、恶性肿瘤、免疫疾病等的患者；4) 入院后48小时内发生死亡或出院的患者。按照左心室射血分数将上述患者分为射血分数降低组(LVEF ≤ 40%)和射血分数保留组(LVEF ≥ 50%)。本研究经医院医学伦理委员会审查通过(批准文号：2021QT037)，所有患者或家属签署知情同意书。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>收集所有患者临床资料，包括性别、年龄、收缩压、舒张压、心率、烟酒史、合并基础疾病情况、2019年1月住院前的长期用药史、实验室指标等。其中实验室指标包括白蛋白、谷丙转氨酶、谷草转氨酶、静脉血糖、糖化血红蛋白A1、尿素氮、尿酸、肌酐、肾小球滤过率(glomerular filtration rate, GFR)、脑利钠肽(brain natriuretic peptide, BNP)、脑钠素N端前体肽(N-terminal pronatriuretic peptide, NT-proBNP)、肌钙蛋白I (troponin I, cTnI)、D-二聚体、C反应蛋白(C-reaction protein, CRP)、总胆固醇(total cholestero, TC)、甘油三酯(triglyceride, TG)、高密度脂蛋白胆固醇(high density lipoprotein cholesterol, HDL-C)、低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C)、同型半胱氨酸(homocysteine, Hcy)。</p><p>门诊或电话随访为每1个月1次，持续1年，记录病人有无再入院或死亡。</p></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>采用SPSS 23.0统计软件进行数据分析。符合正态分布的计量资料以 x &#175; &#177; s 表示，组间比较采用两独立样本t检验；符合偏态分布的计量资料以M(P<sub>25</sub>, P<sub>75</sub>)表示，组间比较采用Wilcoxon秩和检验。计数资料组间比较采用c<sup>2</sup>检验。采用多因素logistic回归分析影响射血分数减少的AHF患者再住院的因素分析。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般情况</title><p>射血分数降低组有94例，再住院率为51.1%，射血分数保留组有68例，再住院率为33.9%，再住院原因均为AHF发作。射血分数降低组1年内死亡率明显高于射血分数保留组，差异有统计学意义(P &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison between the two groups within 1 year of 1 year and the mortalit</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >射血分数减少组(n = 94)</th><th align="center" valign="middle" >射血分数保留组(n = 68)</th><th align="center" valign="middle" >c<sup>2</sup>值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >再住院率[n(%)]</td><td align="center" valign="middle" >48 (51.1)</td><td align="center" valign="middle" >21 (33.9)</td><td align="center" valign="middle" >4.477</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >死亡率[n(%)]</td><td align="center" valign="middle" >22 (23.4)</td><td align="center" valign="middle" >7 (10.3)</td><td align="center" valign="middle" >4.614</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表1. 两组1年内再住院率及死亡率比较</p></sec><sec id="s7_2"><title>3.2. 两组临床特征比较</title><p>射血分数减少组AHF患者收缩压及尿酸、高密度脂蛋白水平均明显低于射血分数保留组的AHF患者(均P &lt; 0.05)，性别、年龄、舒张压、心率、糖化血红蛋白A1、白蛋白、脑利钠肽、脑钠素N端前体肽、肌钙蛋白I水平均明显高于射血分数保留组的AHF患者(均P &lt; 0.05)；差异均有统计学意义(均P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Clinical characteristics of reduced ejection fraction group and reserved ejection fraction grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >临床特征</th><th align="center" valign="middle" >射血分数减少组 (n = 94)</th><th align="center" valign="middle" >射血分数保留组 (n = 68)</th><th align="center" valign="middle" >c<sup>2</sup>/t/Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >男性[n(%)]</td><td align="center" valign="middle" >62 (66.0)</td><td align="center" valign="middle" >26 (38.2)</td><td align="center" valign="middle" >12.221</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >81.00 &#177; 8.24</td><td align="center" valign="middle" >68.58 &#177; 13.72</td><td align="center" valign="middle" >6.638</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >体重指数(kg/m<sup>2</sup>)</td><td align="center" valign="middle" >22.56 &#177; 3.67</td><td align="center" valign="middle" >22.68 &#177; 3.32</td><td align="center" valign="middle" >−0.223</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >住院时间(d)</td><td align="center" valign="middle" >7 (5, 13)</td><td align="center" valign="middle" >7 (5, 11)</td><td align="center" valign="middle" >−0.339</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >收缩压(mmHg)</td><td align="center" valign="middle" >127.12 &#177; 20.58</td><td align="center" valign="middle" >141.185 &#177; 23.65</td><td align="center" valign="middle" >−4.008</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >舒张压(mmHg)</td><td align="center" valign="middle" >77.51 &#177; 14.88</td><td align="center" valign="middle" >72.66 &#177; 14.49</td><td align="center" valign="middle" >2.068</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >心率(次/min)</td><td align="center" valign="middle" >90 (70, 107)</td><td align="center" valign="middle" >77 (69, 91)</td><td align="center" valign="middle" >−2.493</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >吸烟[n(%)]</td><td align="center" valign="middle" >17 (18.1)</td><td align="center" valign="middle" >17 (25.0)</td><td align="center" valign="middle" >1.138</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >饮酒[n(%)]</td><td align="center" valign="middle" >18 (19.1)</td><td align="center" valign="middle" >8 (11.8)</td><td align="center" valign="middle" >1.597</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >高血压[n(%)]</td><td align="center" valign="middle" >55 (58.5)</td><td align="center" valign="middle" >41 (60.3)</td><td align="center" valign="middle" >0.052</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >糖尿病[n(%)]</td><td align="center" valign="middle" >26 (27.7)</td><td align="center" valign="middle" >26 (38.2)</td><td align="center" valign="middle" >2.205</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >冠心病[n(%)]</td><td align="center" valign="middle" >30 (31.9)</td><td align="center" valign="middle" >23 (33.8)</td><td align="center" valign="middle" >0.065</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >扩张型心肌病[n(%)]</td><td align="center" valign="middle" >24 (25.5)</td><td align="center" valign="middle" >21 (30.9)</td><td align="center" valign="middle" >0.563</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >心脏瓣膜病[n(%)]</td><td align="center" valign="middle" >23 (24.5)</td><td align="center" valign="middle" >22 (32.4)</td><td align="center" valign="middle" >1.223</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >贫血[n(%)]</td><td align="center" valign="middle" >10 (10.6)</td><td align="center" valign="middle" >4 (5.9)</td><td align="center" valign="middle" >1.130</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >心房颤动[n(%)]</td><td align="center" valign="middle" >42 (44.7)</td><td align="center" valign="middle" >26 (38.2)</td><td align="center" valign="middle" >0.673</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >抗血小板治疗[n(%)]</td><td align="center" valign="middle" >6 (6.4)</td><td align="center" valign="middle" >8 (11.8)</td><td align="center" valign="middle" >1.447</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >使用胰岛素[n(%)]</td><td align="center" valign="middle" >8 (8.5)</td><td align="center" valign="middle" >13 (19.1)</td><td align="center" valign="middle" >3.935</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >口服降糖药物[n(%)]</td><td align="center" valign="middle" >13 (13.8)</td><td align="center" valign="middle" >8 (11.8)</td><td align="center" valign="middle" >0.149</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >β受体阻滞剂[n(%)]</td><td align="center" valign="middle" >21 (22.3)</td><td align="center" valign="middle" >17 (25.0)</td><td align="center" valign="middle" >0.115</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >ACEI/ARB [n(%)]</td><td align="center" valign="middle" >18 (17.3)</td><td align="center" valign="middle" >17 (21.8)</td><td align="center" valign="middle" >0.578</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >利尿剂[n(%)]</td><td align="center" valign="middle" >15 (14.4)</td><td align="center" valign="middle" >13 (19.1)</td><td align="center" valign="middle" >0.665</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >钙通道阻滞剂[n(%)]</td><td align="center" valign="middle" >20 (21.3)</td><td align="center" valign="middle" >16 (23.5)</td><td align="center" valign="middle" >0.11</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >白蛋白(g/L)</td><td align="center" valign="middle" >35.02 &#177; 3.34</td><td align="center" valign="middle" >33.51 &#177; 4.82</td><td align="center" valign="middle" >2.360</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >谷丙转氨酶(U/L)</td><td align="center" valign="middle" >20 (13, 41)</td><td align="center" valign="middle" >14 (11, 19)</td><td align="center" valign="middle" >−3.702</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >谷草转氨酶(U/L)</td><td align="center" valign="middle" >26 (19, 41)</td><td align="center" valign="middle" >24 (18, 29)</td><td align="center" valign="middle" >−2.471</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >静脉血糖(mmol/L)</td><td align="center" valign="middle" >5.57 &#177; 1.64</td><td align="center" valign="middle" >6.19 &#177; 2.82</td><td align="center" valign="middle" >−1.751</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >糖化血红蛋白-A1 (%)</td><td align="center" valign="middle" >8.1 (7.4, 9.1)</td><td align="center" valign="middle" >8.4 (7.8, 10.1)</td><td align="center" valign="middle" >−2.048</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >尿素氮(mmol/L)</td><td align="center" valign="middle" >8.04 (6.43, 11.88)</td><td align="center" valign="middle" >8.33 (5.79, 8.33)</td><td align="center" valign="middle" >−0.512</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >尿酸(umol/L)</td><td align="center" valign="middle" >544.68 &#177; 149.32</td><td align="center" valign="middle" >443.97 &#177; 133.81</td><td align="center" valign="middle" >4.423</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >肌酐(umol/L)</td><td align="center" valign="middle" >110.3 (84.2, 130.5)</td><td align="center" valign="middle" >102.0 (98.9, 136.8)</td><td align="center" valign="middle" >−0.879</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >GFR [ml/(min&#183;1.73 m<sup>2</sup>)]</td><td align="center" valign="middle" >62.28 &#177; 25.65</td><td align="center" valign="middle" >57.70 &#177; 26.25</td><td align="center" valign="middle" >1.112</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >BNP (ng/L)</td><td align="center" valign="middle" >1291 (786, 2433)</td><td align="center" valign="middle" >421 (267, 993)</td><td align="center" valign="middle" >−6.102</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >NT-proBNP (ng/L)</td><td align="center" valign="middle" >9235 (5015, 15525)</td><td align="center" valign="middle" >3945 (1912, 10127)</td><td align="center" valign="middle" >−4.465</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >cTnI (ug/L)</td><td align="center" valign="middle" >0.054 (0.021, 0.169)</td><td align="center" valign="middle" >0.030 (0.013, 0.082)</td><td align="center" valign="middle" >−2.634</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >D-二聚体(ug/L)</td><td align="center" valign="middle" >910 (550, 1960)</td><td align="center" valign="middle" >860 (452, 2155)</td><td align="center" valign="middle" >−0.608</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >CRP (mg/L)</td><td align="center" valign="middle" >5.0 (1.9, 11.2)</td><td align="center" valign="middle" >7.5 (2.5, 16.9)</td><td align="center" valign="middle" >−1.411</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >TC (mmol/L)</td><td align="center" valign="middle" >3.39 (2.87, 4.14)</td><td align="center" valign="middle" >3.64 (3.16, 4.26)</td><td align="center" valign="middle" >−1.446</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >TG (mmol/L)</td><td align="center" valign="middle" >0.88 (0.70, 1.23)</td><td align="center" valign="middle" >1.05 (0.65, 1.40)</td><td align="center" valign="middle" >−1.022</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >HDL-C (mmol/L)</td><td align="center" valign="middle" >0.91 (0.74, 1.13)</td><td align="center" valign="middle" >1.02 (0.89, 1.28)</td><td align="center" valign="middle" >−2.661</td><td align="center" valign="middle" >&lt;0.05</td></tr><tr><td align="center" valign="middle" >LDL-C (mmol/L)</td><td align="center" valign="middle" >2.03 (1.55, 2.54)</td><td align="center" valign="middle" >2.04 (1.51, 2.33)</td><td align="center" valign="middle" >−1.022</td><td align="center" valign="middle" >&gt;0.05</td></tr><tr><td align="center" valign="middle" >Hcy (umol/L)</td><td align="center" valign="middle" >20.20 &#177; 7.23</td><td align="center" valign="middle" >18.49 &#177; 8.42</td><td align="center" valign="middle" >1.381</td><td align="center" valign="middle" >&gt;0.05</td></tr></tbody></table></table-wrap><p>表2. 射血分数减少组与射血分数保留组临床特征比较</p><p>注：ACEI：血管紧张素转化酶抑制剂；ARB：血管紧张素II受体拮抗剂；GFR：肾小球滤过率；BNP：脑利钠肽；NT-proBNP：脑钠素N端前体肽；cTnI：肌钙蛋白I；CRP：C反应蛋白；TC：总胆固醇；TG：甘油三酯；HDL-C：高密度脂蛋白胆固醇；LDL-C：低密度脂蛋白胆固醇；Hcy：同型半胱氨酸。</p></sec><sec id="s7_3"><title>3.3. 射血分数降低的AHF患者再住院的多因素logistic回归分析</title><p>以射血分数降低的AHF是否再入院为应变量，以上述差异有统计学意义的15个因素为自变量进行多因素logistic回归分析，结果显示性别、年龄、心率、白蛋白、糖化血红蛋白A1、脑利钠肽是影响射血分数降低的AHF患者再住院的独立危险因素(均P &lt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Multivarian Logistic regression analysis of AHF patients with reduced ejection fractio</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >影响因素</th><th align="center" valign="middle" >β</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >Wald χ<sup>2</sup>值</th><th align="center" valign="middle" >P值</th><th align="center" valign="middle" >OR值</th><th align="center" valign="middle" >95%CI</th></tr></thead><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" >−4.155</td><td align="center" valign="middle" >1.243</td><td align="center" valign="middle" >11.176</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >0.016</td><td align="center" valign="middle" >0.001~0.179</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >0.077</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >9.306</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >1.080</td><td align="center" valign="middle" >1.028~1.135</td></tr><tr><td align="center" valign="middle" >心率</td><td align="center" valign="middle" >−0.028</td><td align="center" valign="middle" >0.012</td><td align="center" valign="middle" >5.507</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >0.973</td><td align="center" valign="middle" >0.951~0.995</td></tr><tr><td align="center" valign="middle" >脑利钠肽</td><td align="center" valign="middle" >−0.002</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >12.409</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >0.998</td><td align="center" valign="middle" >0.996~0.999</td></tr><tr><td align="center" valign="middle" >糖化血红蛋白A1</td><td align="center" valign="middle" >0.889</td><td align="center" valign="middle" >0.319</td><td align="center" valign="middle" >7.752</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >2.434</td><td align="center" valign="middle" >1.301~4.552</td></tr></tbody></table></table-wrap><p>表3. 影响射血分数降低的AHF患者再住院的多因素logistic回归分析</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>心力衰竭是由于心脏结构和(或)功能异常，进而出现心室充盈或射血能力受损的一种复杂的临床综合征 [<xref ref-type="bibr" rid="hanspub.44758-ref5">5</xref>]。急性心力衰竭可危及生命，多由心衰或心肌功能障碍急性加重引起 [<xref ref-type="bibr" rid="hanspub.44758-ref6">6</xref>]。随着医疗条件的改善，老年人群心衰患病率上升到10%以上 [<xref ref-type="bibr" rid="hanspub.44758-ref7">7</xref>]。尽管在药物、介入和手术治疗等方案上症状有所改善，但射血分数降低、保留的AHF患者治疗方案不同，预后也存在差异。本文就射血分数降低的AHF患者临床特点及再住院危险因素作一分析，以期为临床诊治提供帮助。</p><p>既往研究报道AHF患者住院期间死亡率约为10% [<xref ref-type="bibr" rid="hanspub.44758-ref8">8</xref>]，本研究结果显示，射血分数减少组1年内死亡率为23.4%，明显高于射血分数保留组组的10.3%。这提示射血分数降低的AHF患者预后很差，可能是多因素作用的结果。</p><p>射血分数降低的AHF患者再住院是多因素作用的结果。射血分数降低组在一些实验室指标上较射血分数保留组存在明显的差异，如糖化血红蛋白A1、尿酸、高密度脂蛋白、白蛋白、脑利钠肽、NT-proBNP、肌钙蛋白I等。糖化血红蛋白A1可以反映过去8~12周平均血糖水平，流行病学研究表明糖尿病是心力衰竭的独立危险因素 [<xref ref-type="bibr" rid="hanspub.44758-ref9">9</xref>]。脑利钠肽是利钠肽的重要组成部分，其含量与心室压力有关，可反映左室心功能，对急性心力衰竭患者的病情转归具有一定的预测价值 [<xref ref-type="bibr" rid="hanspub.44758-ref10">10</xref>]。NT-proBNP同样是利钠肽家族的一员，具有扩张血管作用，因离体后稳定性高，不易变异，目前已作为心力衰竭诊断与预后评价的金标准，已广泛应用于临床 [<xref ref-type="bibr" rid="hanspub.44758-ref11">11</xref>]。陈业媛等 [<xref ref-type="bibr" rid="hanspub.44758-ref12">12</xref>] 研究表明，血清NT-proBNP与急性心力衰竭预后存在明显相关性，本研究结果与之相同。肌钙蛋白I作为一种心肌损伤标志物，参与心肌细胞收缩过程，心肌受损即可释放入血 [<xref ref-type="bibr" rid="hanspub.44758-ref13">13</xref>]，水平升高提示AHF患者发生心脏事件的危险增加，是AHF患者死亡的预测因子 [<xref ref-type="bibr" rid="hanspub.44758-ref14">14</xref>]。高密度脂蛋白胆固醇(HDL-C)水平偏低会增加发生动脉管腔狭窄、动脉粥样硬化、心血管病的风险 [<xref ref-type="bibr" rid="hanspub.44758-ref15">15</xref>]，即高水平HDL-C可以降低心血管病变概率，对机体具有保护作用 [<xref ref-type="bibr" rid="hanspub.44758-ref16">16</xref>]。</p><p>进一步行多因素logistic回归分析，结果显示性别、年龄、心率、白蛋白、糖化血红蛋白A1、脑利钠肽是影响射血分数降低的AHF患者再住院独立危险因素。对于射血分数降低的AHF患者，男性再住院的风险较女性高，收缩压、舒张压及心率偏离正常范围较射血分数保留组明显。研究结果表明射血分数降低的AHF患者心率偏快，1年内再住院率及死亡率较射血分数保留的AHF患者高，心率减慢的患者则有较好的预后，这与前人的研究结果一致 [<xref ref-type="bibr" rid="hanspub.44758-ref17">17</xref>]。在心力衰竭患者中，低蛋白血症比较常见 [<xref ref-type="bibr" rid="hanspub.44758-ref18">18</xref>]。低蛋白血症可加重肺水肿以及外周水肿 [<xref ref-type="bibr" rid="hanspub.44758-ref19">19</xref>]。因此，维持正常水平的白蛋白对射血分数降低的AHF患者具有保护作用。Al-Lawati等 [<xref ref-type="bibr" rid="hanspub.44758-ref20">20</xref>] 研究表明，入院时收缩压低是AHF患者死亡的独立预测因子。毕祥云等 [<xref ref-type="bibr" rid="hanspub.44758-ref21">21</xref>] 研究提示舒张压是影响心力衰竭的独立危险因子，舒张压是男性AHF患者全因死亡的独立预测因子 [<xref ref-type="bibr" rid="hanspub.44758-ref22">22</xref>]。收缩压及舒张压可以反映血管张力和心肌泵功能，过高或过低都会对AHF患者造成不良影响 [<xref ref-type="bibr" rid="hanspub.44758-ref23">23</xref>]。因此，动态监测心率及血压有助于预测射血分数降低的AHF患者预后。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，射血分数降低的AHF患者再住院及死亡风险增加，对于射血分数降低、高龄、男性、合并低蛋白血症、糖化血红蛋白A1及脑利钠肽异常的初次住院治疗的AHF患者，应高度警惕再住院及死亡可能。</p></sec><sec id="s10"><title>文章引用</title><p>吴 飞,王利宏. 射血分数降低的急性心力衰竭患者的临床特点及危险因素分析Analysis of Clinical Characteristics and Risk Factors for Acute Heart Failure Patients with Reduced Ejection Fraction[J]. 临床医学进展, 2021, 11(08): 3652-3658. https://doi.org/10.12677/ACM.2021.118535</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44758-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mentz, R.J. and O’connor, C.M. (2016) Pathophysiology and Clinical Evaluation of Acute Heart Failure. Nature Reviews Cardiology, 13, 28-35. &lt;br&gt;https://doi.org/10.1038/nrcardio.2015.134</mixed-citation></ref><ref id="hanspub.44758-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Brandon Stacey, R., Meng, M., Byrum, I.G., et al. (2016) Clinical Outcomes in Different Types of Aortic Stenosis as Assessed by Doppler Echocardiography. The Journal of Heart Valve Disease, 25, 672-678.</mixed-citation></ref><ref id="hanspub.44758-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">张健, 张宇辉. 多中心、前瞻性中国心力衰竭注册登记研究——病因、临床特点和治疗情况初步分析[J]. 中国循环杂志, 2015, 30(5): 413-416.</mixed-citation></ref><ref id="hanspub.44758-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">王华, 梁延春. 中国心力衰竭诊断和治疗指南2018 [J]. 中华心血管病杂志, 2018, 46(10): 760-789.</mixed-citation></ref><ref id="hanspub.44758-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ponikowski, P., Voors, A.A., Anker, S.D., et al. (2016) 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Revista Española de Cardiología (English Edition), 69, 1167.</mixed-citation></ref><ref id="hanspub.44758-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Kurmani, S. and Squire, I. (2017) Acute Heart Failure: Definition, Classification and Epidemiology. Current Heart Failure Reports, 14, 385-392. &lt;br&gt;https://doi.org/10.1007/s11897-017-0351-y</mixed-citation></ref><ref id="hanspub.44758-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mosterd, A. and Hoes, A.W. (2007) Clinical Epidemiology of Heart Failure. Heart, 93, 1137-1146. 
&lt;br&gt;https://doi.org/10.1136/hrt.2003.025270</mixed-citation></ref><ref id="hanspub.44758-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Emdin, C., Hsiao, A., Kiran, A., et al. (2017) Referral for Specialist Follow-Up and Its Association with Post-discharge Mortality among Patients with Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). The American Journal of Cardiology, 119, 440-444. &lt;br&gt;https://doi.org/10.1016/j.amjcard.2016.10.021</mixed-citation></ref><ref id="hanspub.44758-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Lin, Y., Huang, W., Wu, H., et al. (2021) Association of Mean and Variability of HbA1c with Heart Failure in Patients with Type 2 Diabetes. Journal of Clinical Medicine, 10, 1401. &lt;br&gt;https://doi.org/10.3390/jcm10071401</mixed-citation></ref><ref id="hanspub.44758-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">朱广明. 急性心力衰竭患者血浆BNP水平与心功能及预后的相关性分析[J]. 中国医药指南, 2019, 17(29): 35.</mixed-citation></ref><ref id="hanspub.44758-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nishikimi, T. and Nakagawa, Y. (2019) Does Impaired Processing of Pro-B-Type (or Brain) Natriuretic Peptide Cause Decreased Plasma BNP Levels in Obese Heart Failure Patients? Annals of Translational Medicine, 7, S221. 
&lt;br&gt;https://doi.org/10.21037/atm.2019.08.56</mixed-citation></ref><ref id="hanspub.44758-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">陈业媛, 郑泳森, 柏立辉. 老年急性心力衰竭患者血清NT-proBNP水平及APACHEⅡ评分与预后的相关性研究[J]. 临床医学, 2017, 37(1): 7-9.</mixed-citation></ref><ref id="hanspub.44758-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">曾文莉, 马红梅. 心肌肌钙蛋白I水平联合Tilburg量表对高龄心力衰竭患者预后的判断价值[J]. 心脏杂志, 2020, 32(2): 140-145.</mixed-citation></ref><ref id="hanspub.44758-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kontos, M.C. and Turlington, J.S. (2020) High-Sensitivity Troponins in Cardiovascular Disease. Current Cardiology Reports, 22, Article No. 30. &lt;br&gt;https://doi.org/10.1007/s11886-020-01279-0</mixed-citation></ref><ref id="hanspub.44758-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Potocnjak, I., Degoricija, V., Trbusic, M., et al. (2017) Serum Concentration of HDL Particles Predicts Mortality in Acute Heart Failure Patients. Scientific Reports, 7, Article ID: 46642. &lt;br&gt;https://doi.org/10.1038/srep46642</mixed-citation></ref><ref id="hanspub.44758-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Degoricija, V., Potocnjak, I., Gastrager, M., et al. (2019) HDL Subclasses and Mortality in Acute Heart Failure Patients. Clinica Chimica Acta, 490, 81-87. &lt;br&gt;https://doi.org/10.1016/j.cca.2018.12.020</mixed-citation></ref><ref id="hanspub.44758-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Park, J.J., Park, H.A., Cho, H.J., et al. (2019) Beta-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate. Journal of the American Heart Association, 8, Article ID: e011121. &lt;br&gt;https://doi.org/10.1161/JAHA.118.011121</mixed-citation></ref><ref id="hanspub.44758-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Peterson, E.J., Ng, T.M.H., Patel, K.A., et al. (2018) Association of Admission vs. Nadir Serum Albumin Concentration with Short-Term Treatment Outcomes in Patients with Acute Heart Failure. Journal of International Medical Research, 46, 3665-3674. &lt;br&gt;https://doi.org/10.1177/0300060518777349</mixed-citation></ref><ref id="hanspub.44758-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Peng, W., Zhang, C., Wang, Z., et al. (2019) Prediction of All-Cause Mortality with Hypoalbuminemia in Patients with Heart Failure: A Meta-Analysis. Biomarkers, 24, 631-637. &lt;br&gt;https://doi.org/10.1080/1354750X.2019.1652686</mixed-citation></ref><ref id="hanspub.44758-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Al-Lawati, J.A., Sulaiman, K.J., Al-Zakwani, I., et al. (2017) Systolic Blood Pressure on Admission and Mortality in Patients Hospitalized With Acute Heart Failure: Observations from the Gulf Acute Heart Failure Registry. Angiology, 68, 584-591. &lt;br&gt;https://doi.org/10.1177/0003319716672525</mixed-citation></ref><ref id="hanspub.44758-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">毕祥云, 陈学香, 包振明. 舒张压与80岁以上高血压病人心力衰竭的关系[J]. 实用老年医学, 2017, 31(10): 938-940.</mixed-citation></ref><ref id="hanspub.44758-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Wu, X., Chen, M., Wang, K., et al. (2020) Gender Differences in Prognostic Markers of All-Cause Death in Patients with Acute Heart Failure: A Prospective 18-Month Follow-Up Study. Journal of Cardiovascular Translational Research, 13, 97-109. &lt;br&gt;https://doi.org/10.1007/s12265-019-09893-2</mixed-citation></ref><ref id="hanspub.44758-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Shiraishi, Y., Kohsaka, S., Harada, K., et al. (2016) Correlation of Pre- and In-Hospital Systolic Blood Pressure in Acute Heart Failure Patients and the Prognostic Implications—Report from the Tokyo Cardiac Care Unit Network Emergency Medical Service Database. Circulation Journal, 80, 2473-2481. &lt;br&gt;https://doi.org/10.1253/circj.CJ-16-0837</mixed-citation></ref></ref-list></back></article>